European Commission approves pharma trio’s Ranivisio
Therapy is a biosimilar of Lucentis which treats several serious retinal diseases across the European Union
Read More
Author: John Pinching
Novartis’ Scemblix approved by the EC for adults with chronic myeloid leukaemia
It is estimated that every year more than 6,300 people will be diagnosed with CML in Europe
Read More
NHS leaders urge government to act or risk public health emergency
Senior public health figures take unusual step of warning government about energy costs
Read More
Positive appraisal for Eisai’s Kisplyx in combination with MSD’s Keytruda
NICE approval is for first-line treatment of intermediate and advanced renal cell carcinoma
Read More
New drug application accepted by FDA for GSK’s momelotinib
Therapy for the treatment of myelofibrosis has received significant results from phase 3 trial
Read More- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
